Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi?
Tóm tắt
Primary hyperoxaluria type 1 is a rare genetic disorder caused by bi-allelic pathogenic variants in the AGXT gene leading to an overproduction of oxalate which accumulates in the kidneys in the form of calcium oxalate crystals. Thus, patients may present with recurrent nephrocalcinosis and lithiasis, with progressive impairment of the renal function and eventually kidney failure. There is no specific treatment besides liver-kidney transplantation, and pre-transplantation management by 24 h-hyperhydration, crystallisation inhibitors and high-dose pyridoxine has a high negative impact on quality of life, especially because of the discomfort due to nocturnal hyperhydration. Since 2020, lumasiran, an RNA-interfering therapy, has been approved for the treatment of primary hyperoxaluria type 1 in adults and children. However, to date, there are no recommendations regarding the discontinuation of other supportive measures during RNAi therapy. In this report, we present two patients with primary hyperoxaluria type 1 who were treated with lumasiran and stopped nocturnal hyperhydration with positive outcomes, i.e. normal urinary oxalate, absence of crystalluria, stable kidney function and improved well-being. These data suggest that discontinuing nocturnal hydration may be safe in children responding to lumasiran, and may have a positive impact on their quality of life. Additional data are needed to update treatment recommendations.
Tài liệu tham khảo
Méaux MN, Sellier-Leclerc AL, Acquaviva-Bourdain C, Harambat J, Allard L, Bacchetta J (2022) The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants. Pediatr Nephrol 37(4):907–911. https://doi.org/10.1007/s00467-021-05393-1
Cochat P, Rumsby G (2013) Primary hyperoxaluria. N Engl J Med 369(7):649–658. https://doi.org/10.1056/NEJMra1301564
Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M et al (2012) Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transpl 27(5):1729–1736. https://doi.org/10.1093/ndt/gfs078
Sas DJ, Magen D, Hayes W, Shasha-Lavsky H, Michael M, Schulte I et al (2022) Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children. Genet Med 24(3):654–662. https://doi.org/10.1016/j.gim.2021.10.024
Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O’Riordan WD, Cochat P et al (2021) Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 384(13):1216–1226. https://doi.org/10.1056/NEJMoa2021712
Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM et al (2016) Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 11(1):119–126. https://doi.org/10.2215/CJN.02810315
Biebuyck N, Boyer O (2021) RNA interference therapy may allow withdrawal of nocturnal hyperhydration in children with primary hyperoxaluria. In: ESPN 53rd Annual Meeting, Amsterdam 2021. https://espn2021.org/abstracts/abstract.php?bid=818. https://doi.org/10.1038/s41581-022-00661-1
Hoppe B, Niaudet P, Salomon R, Harambat J, Hulton SA, Van’t Hoff W et al (2017) A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Pediatr Nephrol 32(5):781–790. https://doi.org/10.1007/s00467-016-3553-8
Compagnon P, Metzler P, Samuel D, Camus C, Niaudet P, Durrbach A et al (2014) Long-term results of combined liver-kidney transplantation for primary hyperoxaluria type 1: the French experience. Liver Transpl 20(12):1475–1485. https://doi.org/10.1002/lt.24009
Leflot M, Krzesinski JM, Collard L, Thomas A, Ghuysen MS (2018) Type 1 primary hyperoxaluria: from childhood to adult, how to manage adequately medical therapy compliance? Nephrol Ther 14(3):148–152. https://doi.org/10.1016/j.nephro.2017.06.004
Lawrence JE, Wattenberg DJ (2020) Primary hyperoxaluria: the patient and caregiver perspective. Clin J Am Soc Nephrol 15(7):909–911. https://doi.org/10.2215/CJN.13831119
Rajeev KG, Nair JK, Jayaraman M, Charisse K, Taneja N, O’Shea J et al (2015) Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. ChemBioChem 16(6):903–908. https://doi.org/10.1002/cbic.201500023
Forbes TA, Brown BD, Lai C (2022) Therapeutic RNA interference: a novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol juin 88(6):2525–2538. https://doi.org/10.1111/bcp.14925
Frishberg Y, Deschênes G, Groothoff JW, Hulton SA, Magen D, Harambat J et al (2021) Phase 1/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial. Clin J Am Soc Nephrol juill 16(7):1025–1036. https://doi.org/10.2215/CJN.14730920
Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E et al (2022) Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C Trial. Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2022.05.012